Novo Nordisk sticks to cautious obesity sales goal

Despite an optimistic stock market, Novo Nordisk is not changing its modest guidance of more than doubling its obesity drug sales by 2025.

Photo: Novo Nordisk / PR

Novo Nordisk is stubbornly mantaining its cautious goal for obesity sales in spite of pervasive optimism on the stock market, according to Danish media Børsen.

Industry analysts predict that Novo Nordisk, which is Denmark's largest pharmaceutical company, will grow in the medical division of the obesity market.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs